Clinical Trials
25 trialsNCT07094204 2026-05-18
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT05747625 2026-05-08
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Vanderbilt-Ingram Cancer Center
Phase 1 Recruiting
NCT07543744 2026-04-22
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
R-Pharm
Phase 1 Recruiting
NCT05901545 2026-03-05
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Recruiting
NCT07094113 2026-02-12
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
Phase 1 Recruiting
NCT07021898 2025-12-03
BOREALIS-1
Erasca, Inc.
Phase 1 Recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT06983743 2025-09-11
AURORAS-1
Erasca, Inc.
Phase 1 Recruiting
NCT06194877 2025-04-20
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
MapKure, LLC
Phase 1 Terminated
NCT05084859 2024-08-09
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
Phase 1 Terminated
NCT03733210 2023-05-19
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Stanford University
Phase 1 Completed
NCT03360734 2021-07-12
GATTO
Glycotope GmbH
Phase 1 Completed
NCT02008383 2021-02-12
CaboMAb
Duke University
Phase 1 Completed
NCT01061788 2019-08-28
RAP
Duke University
Phase 1 Completed
NCT00610948 2017-05-04
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00513383 2017-03-01
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Massachusetts General Hospital
Phase 1 Completed
NCT02199223 2016-09-22
Regorafenib + Panitumumab for Colorectal Cancers
University of Utah
Phase 1 Terminated
NCT00658658 2016-05-18
Panitumumab in Children With Solid Tumors
Amgen
Phase 1 Completed
NCT00563316 2016-04-12
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Amgen
Phase 1 Completed
NCT00586443 2014-11-19
BEP
Duke University
Phase 1 Completed
NCT00879385 2014-10-31
KRAS Wild-type Metastatic Colorectal Cancer Trial
University of Utah
Phase 1 Completed
NCT00101907 2014-03-20
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
Amgen
Phase 1 Terminated
NCT00004879 2013-01-08
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT00101894 2012-09-17
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Amgen
Phase 1 Completed
NCT00091806 2009-07-10
Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed